Name (Synonyms) | Correlation | |
---|---|---|
drug680 | Rapid diagnostics using Anyplex TMII RV16 Detection Wiki | 1.00 |
drug254 | Delayed diagnostics Anyplex TMII RV16 Detection Wiki | 1.00 |
drug225 | Convalescent Plasma Wiki | 0.35 |
Name (Synonyms) | Correlation | |
---|---|---|
D005335 | Fever of Unknown Origin NIH | 1.00 |
D002637 | Chest Pain NIH | 1.00 |
D004417 | Dyspnea NIH | 0.58 |
D014777 | Virus Diseases NIH | 0.11 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0100749 | Chest pain HPO | 1.00 |
HP:0002098 | Respiratory distress HPO | 0.71 |
There is one clinical trial.
The purpose of this study is to find out if transfusion of blood plasma containing antibodies against COVID-19 (anti-SARS-CoV-2), which were donated from a patient who recovered from COVID-19 infection, is safe and can treat COVID-19 in hospitalized patients. Antibodies are blood proteins produced by the body in response to a virus and can remain in the person's bloodstream (plasma) for a long time after they recover. Transferring plasma from a person who recovered from COVID-19 may help neutralize the virus in sick patients' blood, and/or reduce the chances of the infection getting worse.
Description: Number of days a patient is receiving mechanical invasive ventilation through 28 days post randomization. Patients who die during this time period are assigned 0 ventilator free days.
Measure: 28 day ventilator free days Time: 28 days post randomizationDescription: All cause mortality from randomization until 90 days post randomization
Measure: 90 day all-cause mortality Time: 90 days